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MAP4DNAL1 and MAP4 are both microtubule-associated proteins. These proteins were identiﬁed as HIV-1 depen-
dency factors in a screen with wild-type HIV-1. In this study we demonstrate that knockdown using DNAL1
and MAP4 siRNAs and shRNAs inhibits HIV-1 infection regardless of envelope. Using a fusion assay, we show
that DNAL1 and MAP4 do not impact fusion. By assaying for late reverse transcripts and 2-LTR circles, we
show that DNAL1 and MAP4 inhibit both by approximately 50%. These results demonstrate that DNAL1
and MAP4 impact reverse transcription but not nuclear translocation. DNAL1 and MAP4 knockdown cells
do not display cytoskeletal defects. Together these experiments indicate that DNAL1 and MAP4 may exert
their functions in the HIV life cycle at reverse transcription, prior to nuclear translocation.llo), thope@northwestern.edu
rights reserved.© 2011 Elsevier Inc. All rights reserved.Introduction
Like many viruses, the Human Immunodeﬁciency Virus (HIV) as-
sociates with the host cell cytoskeleton immediately after entry, and
is dependent on it for the formation of subcellular complexes and
trafﬁcking during the early events of infection (Campbell and Hope,
2005; Greber and Way, 2006; Radtke et al., 2006). Consequently, mi-
crotubule integrity, functional cellular motors, and the reorganization
of the actin network are necessary requirements for the successful cy-
toplasmic deposition of HIV cores and progression through the early
events of infection (Bukrinskaya et al., 1998; McDonald et al., 2002;
Naghavi and Goff, 2007).
As early as fusion, HIV depends on a reorganization of the actin cy-
toskeleton for deposition of the viral core into the cytoplasm. Several
studies suggest that cortical actin plays an active role in the clustering
of CD4 and CXCR4 receptors for successful fusion of viral and cellular
membranes (Iyengar et al., 1998; Jimenez-Baranda et al., 2007; Pontow
et al., 2004). This action is mediated by cellular factors such as coﬁlin
and LIMK1, which are upregulated in response to CXCR4 engagement
by viral glycoprotein gp120 (Bukrinskaya et al., 1998; Stolp et al.,
2009; Yoder et al., 2008). Following fusion, the cortical actin representsa physical obstacle (Campbell et al., 2004; Wu and Yoder, 2009; Yoder
et al., 2008) that the released HIV core must overcome before progres-
sing through to the cytoplasm.
After fusion, the viral core must navigate through the viscous cyto-
plasm to the nucleus where it can integrate into the host chromo-
somal DNA and establish infection. As with many viruses and
macromolecular cellular cargoes, retrograde trafﬁcking of HIV across
the cytoplasm is accomplished on microtubules by the ATP-depen-
dent molecular motor dynein (McDonald et al., 2002). As the viral
cores navigate through the cytoplasm, they must successfully reverse
transcribe their RNA genome into cDNA giving rise to a reverse tran-
scription complex (RTC). During reverse transcription, the RTC must
shed the p24 capsid (CA) shell that surrounds the viral core and gene-
rate the viral cDNA for integration (Hulme et al., 2011). Previous
studies have utilized ﬂuorescently labeled viral complexes to show
that particles progress through uncoating during reverse transcrip-
tion while trafﬁcking on microtubules (Arhel et al., 2006; McDonald
et al., 2002). These studies also demonstrated a relative accumulation
of viral complexes proximal to the nucleus at 2 hours post-infection,
while conversely demonstrating the accumulation of complexes at
the cell periphery when the dynein motor complex is inhibited
(McDonald et al., 2002). Together these studies highlight some of
the dependencies that HIV has on the host cytoskeleton as it pro-
gresses through the early stages of infection.
While the dependency of HIV on the cell cytoskeleton and cellular
motor proteins has been documented in multiple independent studies,
the speciﬁc interactions between infecting viral cores and cytoskeletal
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ized. Moreover, modulation of these interactions early in infection has
primarily relied on broadly acting pharmaceutical agents such as noco-
dazole, vinblastine, cytochalasins, latrunculin B, or jasplakinolide,
which disrupt or stabilize cytoskeleton networks (Bukrinskaya et al.,
1998; Campbell et al., 2004; Jolly et al., 2007; Yoder et al., 2011). The
broad effects of these drugs make it difﬁcult to determine the effects
that speciﬁc cytoskeletal components have on HIV reverse transcrip-
tion, uncoating, and trafﬁcking.
Recent genome-wide siRNA screens aimed at identifying HIV-1
dependency factors have uncovered hundreds of cellular factors that
may be required for HIV infection at various stages of the life cycle
(Brass et al., 2008; Bushman et al., 2009; Konig et al., 2008). Of partic-
ular interest are those factors that may facilitate the early events of
infection, following fusion, but prior to integration, since these may
highlight the speciﬁc cellular factors that interact with HIV cores to
facilitate reverse transcription, uncoating, retrograde trafﬁcking and
nuclear translocation.
In an effort to identify factors that facilitate these early events in in-
fection, we characterized a subset of screened cellular proteins with
documented or predicted roles in cytoskeleton structure and function.
Using siRNAs to these proteins, we were able to identify two proteins,
Dynein Axonemal-Light Chain 1 (DNAL1) and Microtubule Associated
Protein 4 (MAP4), which are necessary for infection independent of
viral entry pathway. MAP4 has been characterized as a microtubule
binding protein that is expressed in many types of tissues including
muscle (Sato et al., 1997) and brain (Tokuraku et al., 2010). Overexpres-
sion ofMAP4 results in over-decoration ofmicrotubules. Several studies
have documented inhibition of intracellular microtubule-based trans-
port as a result of this over-decoration (Bulinski et al., 1997; Cheng
et al., 2005; Nguyen et al., 1997). DNAL1 was previously identiﬁed as
the human ortholog of the chlamydomonas outer dynein arm axonemal
light chain 1 protein (Horvath et al., 2005). Recently, a homozygousmu-
tation of the protein was determined to be one of the causes of primary
ciliary dyskinesia (Mazor et al., 2011). In these studies, DNAL1 mRNA
expressionwas documented in lymphoblastoid cells,making its expres-
sion relevant to HIV infection. Here we deﬁne the requirement of MAP4
and DNAL1 in the early events of HIV infection.
Results
DNAL1 and MAP4 siRNA knockdowns inhibit HIV-1 infection
In an effort to identify cytoskeletal proteins that facilitate the early
events of infection, we focused on 10 proteins that were initially iden-
tiﬁed as necessary for expression of viral proteins, following a single
cycle of infection (Brass et al., 2008). These proteins include CAPN6,
DNAL, FLII, FGD6, MAP4, MID1lP1, SPAST, SPTAN1, SPTBN, and
ZNF354A. To verify the viral requirement for each proposed HIV-1 de-
pendency factor, HeLa P4.2 cells were transfected with pools of 4 siR-
NAs to each of the cytoskeleton protein for 48 h. After transfection,
the siRNA-treated cells were infected with either R7X4-GFPHIV
(Fig. 1A) or VSV-G pseudotyped R7ΔenvGFPHIV (Fig. 1B). Infected
cells were analyzed by ﬂow cytometry and normalized to control
cells transfected with the non-targeting siRNA control #4 (NT4).
These results show that the envelope protein on the surface of the
virus yielded different abilities to infect the siRNA-treated cells.
While all 10 siRNAs consistently decreased R7X4-GFP infection by
40% or greater, only DNAL1 and MAP4 consistently inhibited infection
of VSV-G pseudotyped virus to the same extent. Since DNAL1 and
MAP4 siRNAs inhibit HIV infection to a similar extent in both X4
and VSV-G pseudotyped viruses, we hypothesized that DNAL1 and
MAP4 function at a step after viral entry.
We next assessed the level of DNAL1 and MAP4 knockdown. For
MAP4, P4.2 cells were transfected with the siRNA pool, to MAP4 for
48 h. Cells were then lysed and analyzed by western blot for MAP4expression levels (Fig. 1C). Relative to control cells, MAP4 siRNA
transfected cells exhibited markedly lower expression of MAP4 pro-
tein. Previous studies demonstrated that DNAL1 was expressed in tes-
ticular tissue and lymphoblastoid cells, however, its expression in
HeLa cells has not previously been documented (Campbell et al.,
2004; Horvath et al., 2005; Mazor et al., 2011). Since DNAL1 monoclo-
nal antibodies are not commercially available, we instead quantiﬁed
DNAL1 mRNA in P4.2 cells that were transfected with DNAL1 siRNA
(pool) or NT4 for 48 h. Total mRNA was isolated, reverse transcribed,
and subsequently ampliﬁed with DNAL1-speciﬁc primers via real-
time PCR, to obtain relative levels of DNAL1 cDNA. Copies of β-actin
were also determined via quantitative PCR, and the number of
DNAL1 cDNA/1000 copies of β-actin was calculated to yield relative
expression levels in treated cells. The results demonstrate that
DNAL1 mRNA is expressed in HeLa cells and that DNAL1 siRNA treat-
ment was functional in decreasing mRNA expression.
Since all previous experiments relied on pools of 4 siRNAs, we
next chose to use individual siRNAs to both minimize off-target ef-
fects, and to ensure that multiple siRNAs reproducibly inhibit HIV-1
infection. As before, we assessed protein expression of MAP4 or
mRNA expression of DNAL1 after 48-hour siRNA transfections. In
these cells, treatment with the individual MAP4 siRNAs #2 and #4
and DNAL1 siRNAs #3 and #4 resulted in similar levels of expression
knockdown (Figs. 1C and D), and HIV infectivity impairment (Figs. 1 E
and F). While all four of the siRNAs in the pool decreased expression
to various extents, we chose to pursue experiments with these two,
which yielded the strongest effects. To ensure that the siRNA effect
was speciﬁc to infection and not a general effect on reporter expres-
sion, we transfected cells with GFP and R7ΔenvGFPHIV at 48 h post
siRNA transfection and assessed GFP expression via ﬂow cytometry
(Fig. 1G). These results indicate that the defect in infectivity associat-
ed with the siRNAs is reproducible, speciﬁc to the siRNA treatment,
and is not a defect in cellular transcription.
DNAL1 and MAP4 knockdowns function after HIV-1 fusion to inhibit
reverse transcription and 2-LTR formation
We next sought to identify the stage of the viral life cycle in which
DNAL1 and MAP4 exert their effects on infection. To accomplish this,
we assayed the ability of viral complexes to progress through fusion,
reverse transcription and nuclear translocation. Since DNAL1 and
MAP4 may affect trafﬁcking or cytoskeletal function, defects in pro-
gression toward the nucleus may be exposed through these assays.
To further exclude the possibility that DNAL1 and MAP4 function
at the entry step of the HIV life cycle we assayed knocked-down
cells for defects in fusion. For this experiment we employed a previ-
ously described Beta-Lactamase (BLam) Fusion Assay (Cavrois et al.,
2004). In this assay, cells are infected with a virus containing the
beta-lactamase protein, then loaded with a ﬂuorescent substrate to
the enzyme. Conversion of the substrate from green to blue is only ac-
complished after fusion of the virions, and cytoplasmic release of the
enzyme. This color conversion is subsequently analyzed by ﬂow cyto-
metry. For these experiments, HeLa P4.2 cells were transfected with
siRNAs to CD4, DNAL1 or MAP4. At 48 h after transfection, cells
were infected with R7X4-GFPHIV/Vpr-BLam virus by spinoculation
at 16 °C, to synchronize infection, for 2 h and then incubated at
37 °C for 3 h. Cells were then loaded with CCF2-AM for 14 h and ana-
lyzed by ﬂow cytometry. Relative to cells that were mock transfected,
DNAL1 and MAP4 did not impact HIV-1 fusion. Contrarily, CD4-siRNA
transfected cells showed a N90% decrease in fusion, when compared
to the negative control (Fig. 2A). These results agree with the infectiv-
ity studies, which suggest that DNAL1 and MAP4 act at a stage follow-
ing viral entry.
The impact of siRNA transfection on late reverse transcript forma-
tion and 2-LTR circle formation was also assessed in HeLa P4.2 cells.
The siRNA-transfected cells were infected by synchronized infection
Fig. 1. SiRNA transfections targeting cytoskeletal proteins. (A and B) Percent infectivity of GFP reporter R7X4-GFPHIV (A) and VSV-G R7ΔenvGFPHIV (B) in HeLa P4.2 cells 48 h post-
infection. Infectivity is normalized to infection in control cells transfected with non-targeting siRNA #4(NT4). Experiments are representative of 4 independent experiments. Error
bars represent standard deviation of triplicate samples within an experiment. (C) MAP4 western blot analysis on cellular extracts from HeLa P4.2 cells transfected with either
pooled siRNAs or individual siRNAs to MAP4. (D) Reverse Transcription PCR analysis of DNAL1 expression in HeLa P-4.2 cells transfected with NT4, pooled siRNAs, or individual
siRNAs to DNAL1. (E and F) R7X4-GFP and VSV-G GFP infectivity in HeLa P4.2 cells was assessed following 48-hour transfection with MAP4 siRNAs #2 and #4 (E), and DNAL1 siRNAs
# 3 and #4 (F). Infectivity was normalized to siRNA transfection controls, transfected with NT4 (G) Protein expression levels in siRNA-transfected cells were assessed 48 h after
siRNA transfection by transfection with GFP or R7Δenv GFP expression plasmids. Cells were analyzed by ﬂow cytometry. Graphs are representative of 3 independent experiments.
Error bars represent the standard deviation of triplicate experiment samples within an experiment.
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virus was washed and infection was allowed to proceed for 24 h.
Cells were harvested, and total genomic DNA was isolated. The num-
ber of late reverse transcripts and 2-LTR circles was then determined
by quantitative PCR analysis and normalized to copies of β-actin.Reverse transcription was inhibited by approximately 50% in DNAL1
and MAP4 siRNA-treated cells, with DNAL1 siRNA #3 and MAP4
siRNA #4 having the greatest effect (Fig. 2B). The formation of 2-LTR
products was also inhibited in DNAL1 and MAP4 siRNA-transfected
cells by approximately 50% (Fig. 2C).
Fig. 2. Fusion, reverse transcription and 2-LTR formation in MAP4 and DNAL1 silenced cells. (A) A representative fusion assay (n=3) in DNAL1 and MAP4 siRNA knocked down
cells. HeLa P4.2 cells were transfected with listed siRNAs for 48 h then infected with R7X4-GFPHIV/Vpr-BLam, loaded with CCF2, and assessed for CCF2 cleavage to determine rel-
ative levels of fusion. (B and C) Late reverse transcripts (B) and 2-LTR circles (C) were assessed at 24 h after infection, following a 48-hour siRNA transfection, by quantitative-PCR.
Copies of late reverse transcripts and 2-LTR circles were normalized to copies of β-actin to yield relative copies per cell. Error bars indicate the standard deviation within triplicate
samples. Results are representative of 5 independent experiments.
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ther DNAL1 shRNA (DNALsh) or MAP4 shRNA (MAP4sh), along with a
TurboGFP reporter. As a result, transduced cells are all GFP-positive.
First, knockdown of both proteins was assessed by western blot or
RT-PCR, as in the siRNA-treated cells, and the results were similar to
those in Fig. 1 (Data not shown). Next, the shRNA cell lines were
assessed for general defects in protein expression by transfectionwith an RFP expression vector. Both MAP4sh and DNAL1sh shRNA
lines were within 15–20% of the levels of RFP expression when com-
pared to the Non-Targeting shRNA control cell line (NONsh) (Fig. 3A).
We next veriﬁed that the knockdown cell lines were capable of
inhibiting infection as well as late reverse transcript formation and
2-LTR circle formation, as documented in siRNA transfections. Both
MAP4sh and DNAL1sh cell lines inhibited HIV infection, as measured
Fig. 3. HIV, MLV, and HSV-1 infectivity in DNAL1 and MAP4 shRNA-expressing cell lines. (A) Control plasmid expression levels were assessed by 24-hour transfection of an RFP
expression plasmid, and analyzed by ﬂow cytometry. (B) VSV-G pseudotyped NL4-3-Luciferase infectivity in monoclonal cell lines was assessed by 48 h infection (n=7). For all
luciferase infectivity assays, a representative experiment is shown over three dilutions within the linear range. Error bars represent standard error of the mean (SEM) among trip-
licate experiment samples. Luciferase activity was normalized by cell count. (C and D) Late reverse transcripts(C) and 2-LTR circles/cell (D) were assessed following a 24-hour in-
fection with NL4-3-Luc. Error bars represent SD within triplicate samples. (E) VSV-G pseudotyped N74D HIV-Luciferase infectivity in monoclonal cell lines (n=4). (F) VSV-G
pseudotyped MLV Luciferase infectivity in monoclonal cell lines (n=7). (G) Susceptibility to HSV-1 infection was assessed by a 48-hour infection with RFP-HSV-1 over three di-
lutions in the linear range (n=3). Cells were analyzed by ﬂow cytometry analysis of the RFP+population of cells.
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Over 7 independent experiments, MAP4sh decreased HIV-1 infection
by an averaged 78% (+/− SEM 2.7%, pb .001) while DNALsh de-
creased infection by 85% (+/− SEM 2.4%, pb .001). Similarly, late re-
verse transcripts/cell and 2-LTR circles/cell were decreased by about
50% in both DNAL1sh and MAP4sh cell lines (Figs. 3C and D).
In previously published studies, the N74D CA mutant has been
demonstrated to overcome HIV's dependence on the cellular protein
TNPO3 for nuclear translocation, instead entering the nucleus via a
different cellular pathway ( Lee et al., 2010). To test if this mutant
could also over come the requirement for MAP4 and DNAL1, we
infected the cell lines with N74D-Luciferase virus. Infection levels
were also decreased by approximately 66% (+/− SEM 4.6%, pb .01)
and 62% (+/− SEM 4.8%, pb .01) for MAP4sh and DNAL1sh respec-
tively (n=4) (Fig. 3E). Together with the quantitative PCR data this
data argues that DNAL1 and MAP4 likely do not mediate nuclear
translocation, and do not exert variable effects on capsid mutant
viruses.
An inhibition of 2-LTR circle formation, with little or no impact to
reverse transcription is believed to identify factors required for nucle-
ar translocation, since reverse transcription takes place in the cyto-
plasm, while 2-LTR circle formation takes place in the nucleus
(Christ et al., 2008). However, since both DNAL1 andMAP4 siRNAs in-
hibit 2-LTR circle formation to levels similar to the late reverse tran-
script formation, DNAL1 and MAP4 likely do not function in nuclear
translocation. Instead, the observed decreases in 2-LTR circles and
late reverse transcripts indicate a potential requirement for DNAL1
and MAP4 during reverse transcription.
Infection of shRNA-expressing cell lines with HIV, MLV, and HSV-1
demonstrates retroviral speciﬁcity for MAP4
We next sought to identify if the effects of MAP4 and DNAL1
knockdown were speciﬁc to HIV, or similarly exerted on distinct vi-
ruses. For these experiments we tested the ability of two distinct vi-
ruses with different life cycles, MLV and HSV-1, to infect DNAL1 and
MAP4 shRNA-expressing cell lines. As a retrovirus that is incapable
of infecting dividing cells, MLV provides further opportunity to deter-
mine if MAP4 and DNAL1 function at nuclear translocation, while also
revealing the level of speciﬁcity these proteins have to lentiviral ver-
sus retroviral life cycles. As a structurally distinct virus, which also re-
lies on microtubule trafﬁcking, HSV-1 provides the opportunity to
further assess the viral speciﬁcity of these proteins.
While our results indicate that DNAL1 and MAP4 are required for
HIV infection, we chose to further explore the impact of these proteins
on other viruses, with the aimof revealing any potential viral speciﬁcity.
We ﬁrst infected DNAL1sh and MAP4sh lines with MLV-Luciferase
(Fig. 3F). The results demonstrated an MLV dependency on both
DNAL1 and MAP4, although the effect was weaker than observed with
HIV, with a 41% (+/− SEM 5.7%, pb .01) and 40% (+/− SEM 6.1%,
pb .01) decrease in infectivity for MAP4sh and DNAL1sh respectively
(n=7). Since DNAL1 and MAP4 knockdowns similarly impact lentivi-
ruses and retroviruses in general, we next tested their requirement in
the cellular infection of HSV-1, an unrelated virus. HSV-1 is an envel-
oped linear double-stranded DNA virus, with an icosahedral capsid.
For these experiments we infected shRNA cell lines with an mRFP-re-
porter HSV-1 (n=3) (Fig. 3G). Unlike wildtype CA HIV, N74D HIV and
MLV, the MAP4sh line did not alter HSV-1 infection. Over three inde-
pendent experiments MAP4sh showed an averaged 114% (+/− SEM
6.0%) infection rate relative to the NONsh control cell line. However,
the DNAL1sh line did inhibit HSV-1 infection by approximately 58%
(+/− SEM 6.0%) relative to controls. These results indicate that
DNAL1 is required for optimal infectionwith HIV, aswell as retroviruses
such asMLV, and HSV-1. Together, these results suggest that the role of
DNAL1 in the viral life cycle of HIV may be the result of a general effect
on microtubule-dependent trafﬁcking. On the other hand, MAP4appears to be necessary for HIV and MLV, but not HSV-1, indicating
that it exhibits some functional speciﬁcity in retroviral life cycles.
DNAL1 and MAP4 knockdown does not disrupt the cytoskeleton
Since DNAL1 and MAP4 function in the early events of infection,
after fusion but prior to integration, it is possible that they mediate
their effects on the viral life cycle by interaction with the cytoskele-
ton. In the absence of DNAL1 monoclonal antibodies, we assessed cy-
toskeletal and trafﬁcking function by immunoﬂuorescent staining of
DNALsh and MAP4sh knockdown cells. DNAL1 and MAP4 shRNA
cell lines were stained for β-Tubulin, MAP4 and the trans-golgi net-
work protein 46 (TGN46) (Fig. 4). When compared to NONsh cells,
DNALsh and MAP4sh did not show microtubule morphological de-
fects (Fig. 4). When microtubule-dependent trafﬁcking is perturbed,
the perinuclear localization of TGN-46 is disrupted, yielding a dis-
persed cytoplasmic localization (Cobbold et al., 2004). Neither
MAP4sh nor DNAL1sh showed this disrupted localization. DNALsh
and MAP4sh cells were also stained for MAP4. DNAL1 knockdown
did not affect the localization of this microtubule associated protein,
however MAP4sh shows a clear decrease in MAP4 expression relative
to NONsh. These results indicate that neither DNAL1 nor MAP4
knockdown results in disruption of the cytoskeleton, or impairment
of cell-wide trafﬁcking.
Discussion
The early events of HIV-1 infection, consisting of viral fusion, cap-
sid uncoating, reverse transcription, retrograde trafﬁcking of viral
complexes, and nuclear translocation, are a continuing focus of HIV-
1 characterization studies. Recent advances in the ﬁeld have
highlighted the role of cellular factors at every step of the early events
of infection. However the role that the cytoskeleton plays in uncoat-
ing and in the formation of reverse transcription complexes is still
not clear. Although previous studies document a defect in infection
when the cytoskeleton is entirely disrupted, the speciﬁc cytoskeletal
proteins that facilitate the early infection events, possibly via direct
interaction with viral proteins, remain undeﬁned.
New approaches to studying the early events of infection via
siRNA-mediated knockdown of cellular proteins have identiﬁed and
conﬁrmed the requirement of a multitude of cellular factors that are
necessary for fusion and nuclear translocation (Brass et al., 2008;
Konig et al., 2008). Moreover, similar studies highlight the ability of
certain viral mutants to overcome the observed requirement for cel-
lular proteins in siRNA-treated cells ( Lee et al., 2010). DNAL1 was
originally documented as the chlamydomonas outer arm dynein axo-
nemal light chain 1(Horvath et al., 2005). However, its expression in
HeLa cells had not previously been documented. MAP4 is a widely
characterized protein with distinct functions in neuronal and cardiac
tissues.
Here we show that DNAL1 and MAP4 are expressed in HeLa cells,
and that their expression can be silenced by transfection of either siR-
NAs or shRNAs. SiRNA-mediated knockdown of MAP4 and DNAL1 in-
hibits HIV-1 infection by more than 50% relative to controls. Based on
the results from our fusion assays, quantitative PCR experiments, and
N74D infectivity, this inhibition maps to a step after fusion, but prior
to nuclear translocation. Speciﬁcally, the ability of HIV to reverse-
transcribe its RNA genome is inhibited by more than 50% after knock-
down, as is 2-LTR formation. This indicates that dependency on
DNAL1 and MAP4 occurs during, or prior to, reverse transcription.
Recent studies have suggested the use of different HIV-1 infection
pathways when required cellular factors are silenced with siRNAs.
One such example shows that TNPO3 is required for nuclear transloca-
tion, but its absence in siRNA-transfected cells can be overcome by a
single amino acid mutation at position 74 of capsid (N74D). Similarly
to previous experiments on TNPO3 dependency, we infected DNAL1
Fig. 4. Microtubule integrity and intracellular trafﬁcking in DNAL1 and MAP4 shRNA-expressing cell lines. Defects in cytoskeletal morphology were analyzed by immunoﬂuores-
cence staining for β-Tubulin and MAP4. Defects in trafﬁcking were assessed by staining for the trans-golgi network protein 46. Fluorescent intensities were normalized to control
cells.
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inhibited by a lack of DNAL1 and MAP4, indicating that DNAL1 and
MAP4 do not exert variable effects on CA mutant viruses. To further
conﬁrm this, we also tested other previously characterized HIV CA
mutants (E45A, N74D, Q63A, T54A/N57A, G89V, P90A, G94D, A92E)
in siRNA-treated cells, but no mutants were able to overcome the de-
pendency on DNAL1 andMAP4 for infection, since infectionwas inhib-
ited by more than 50% in all cases (data not shown).
As a lentivirus, HIV is capable of infecting non-dividing cells. By test-
ing the dependence ofMLV, a retrovirus that cannot infect non-dividing
cells, onMAP4 and DNAL1we show that both proteins are generally re-
quired for retroviral infection. A small difference in viral susceptibility
was observed between HIV and MLV infection assays. This difference
may be the result of structural differences in the capsid core or RTC, dif-
ferences in the process of uncoating, or variations in their relative re-
quirements for microtubule association. The disparate ability of
DNAL1 knockdown to inhibit HSV-1 infection,whereMAP4 knockdown
fails to inhibit it, demonstrates that there is speciﬁcity in the viral re-
quirement for MAP4. As a structurally different virus, which does not
undergo reverse transcription, HSV-1 shows no dependence on MAP4,
instead demonstrating a slight increase in infection in the absence of
MAP4. HSV-1 however does demonstrate a dependence on DNAL1.
RFP transfection experiments and ﬂuorescence imaging exclude the
possibility that these results are the outcome of general effects on pro-
teins expression and cell toxicity respectively.
Altogether, these results help demonstrate an siRNA-speciﬁc and
reproducible, post-fusion, and pre-nuclear translocation impairment
of HIV-1 infection in tested cells. While DNAL1 had previously beendescribed as having a function in ciliary cells, and more recently as
a facilitator of dynein heavy chain and tubulin binding (Mazor et al.,
2011), its requirement in the intracellular events of HIV have not pre-
viously been described. Similarly, MAP4 is often associated with pa-
thologies when it is upregulated or overexpressed, however, there
have not been studies on the cellular effects of its down-regulation.
Previously published results indicate that successful formation of
an RTC and generation of late reverse transcription products were
conﬁned to cytoskeletal and nuclear fractions, indicating a role of cy-
toskeletal association in RTC formation (Bukrinskaya et al., 1998).
Those studies relied primarily on cytochalasins, inhibitors of actin po-
lymerization, and thus argued that actin microﬁlaments were re-
quired for RTC formation and RT. Our results show that generation
of late reverse transcription products may involve cytoskeletal com-
ponents other than actin. DNAL1 and MAP4 are both documented mi-
crotubule associated proteins. The ability of MAP4 knockdown to
inhibit infection of HIV and MLV further argues that MAP4 may
have a speciﬁc interaction with RTC components of retroviruses,
while different levels of dependency may be the result of differences
in cellular interactions that result in variations in the early events of
infection. DNAL1 on the other hand, also impacted reverse transcrip-
tion of HIV-1, but was not speciﬁc to retroviruses, since HSV-1 was
also dependent on the protein. DNAL1 has been documented to link
components of the cytoskeleton with the molecular motor dynein,
perhaps acting as a scaffold for larger functional structures. Both
DNAL1 andMAP4may be impacting reverse transcription by affecting
the formation of RTCs on microtubules or by impacting RTC associa-
tion with microtubules. However, further studies are needed to
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Recently published studies document an interdependence between
reverse transcription and uncoating (Hulme et al., 2011). Future stud-
ies on HIV's requirement for DNAL1 and MAP4 in uncoating may pro-
vide further insight into their roles in reverse transcription.
Materials and methods
Cell Culture and siRNA transfections
293T cells, HeLa cells, HeLa P-4.2 cells and shRNA stably transduced
cell lines were cultured at 37 °C and 5% CO2 in DMEM (HyClone) sup-
plemented with 10% FBS, 100 units/ml penicillin, 100 μg streptomycin,
292μg/ml L-glutamine. Additionally shRNA stably transduced cell lines
were kept under 5 μg/ml puromycin (Sigma) selection.
Virus production
Virus was produced in 10-cm dishes of 293T cells as previously
described (Anderson et al., 2006). Brieﬂy, for HIV viruses, cells were
transfected with 12 μg of viral cDNA expression plasmids: R7ΔenvGF-
PHIV, R7X4-GFPHIV (Hulme et al., 2011), NL4-3Δenv Luciferase (Lee
et al., 2010), N74D-Luciferase, and 4 μg of VSV-G expression plasmid
(for proviral plasmids lacking envelope) and using 35 μl of 10 μg/ml
polyethylenimine (PEI) (molecular weight, 25,000; Polysciences).
The NL4-3 Luciferase plasmid was a gift from Dr. Vineet N. KewalRa-
mani (NCI Frederick National Cancer Institute). For BLam assays, virus
was produced by transfection with 12 μg R7X4-GFPHIV and 2 μg Vpr-
BLam (Cavrois et al., 2004), For MLV-Luciferase reporter virus 293T
cells were transfected with 7 μg FB-Luc (Stratagene), 7 μg of pCG
Gag-Pol (Shun et al., 2007), and 4 μg VSV-G. The pCG Gag-Pol plasmid
was a gift from A. Engleman (Dana-Farber Cancer Institute, Harvard
University, Boston, MA). Virus was harvested as previously described
(Anderson et al., 2006; Hulme et al., 2011). HSV-1 was produced by
infecting a conﬂuent 10 cm plate of Vero cells with Pseudorabies
Virus-psuedotyped HSV-1 that contains an mRFP1-VP26 fusion. Pro-
duced virus was harvested at approximately 2 days after infection,
following cell rounding. HSV-1 mRFP-VP26 was a generous gift from
Greg Smith (Feinberg School of Medicine, Northwestern University,
Chicago, IL).
siRNA transfections and infections
All siRNA transfections were carried out in HeLa P4.2 cells, which
express the CD4 and CXCR4 cellular receptors (NIH AIDS Research
and Reference Reagent Program). HeLa P4.2 cells were seeded at a
density of 50,000 cells/well in a 24-well dish. Cells were transfected
with each of the indicated siRNAs at a ﬁnal concentration of 10 μM.
After 24 h of transfection cells were then re-seeded in 96-well dishes
at a density of 10,000/well for infectivity assays. At 48 h after siRNA
transfection cells were then infected with either R7X4-GFPHIV re-
porter virus or VSV-G-pseudotyped R7Δenv-GFP HIV reporter virus.
To assess virus infectivity, HeLa P4.2 cells were infected by serial dilu-
tions of viral stocks. For all subsequent experiments, viral infections
were analyzed using amounts of virus resulting in the linear infection
range. GFP expression was determined at 48 h after infection by using
an Accuri C6 96-well ﬂow cytometer.
Creation of shRNA cell lines
HeLa cells were transduced with lentiviral vectors expressing
shRNAs to either MAP4 or DNAL1. The shRNA constructs targeting
MAP4 (V2LHS_151564) and DNAL1 (V2LHS_118241) sequences
were obtained from Open Biosystems. Lentiviral vector was produced
in 293T cells by co-transfecting 7 μg each of the shRNA plasmids, VSV-
G plasmid and Δnrf (Xu et al., 2001), using 35 μl of 10 μg/ml of PEIinto a 10 cm plate. Media was changed at 24 h post transfection and
media containing lentiviral vector was harvested at 48 h post trans-
fection. Forty-eight hours after transducing, cells were aliquoted
into 96 well plates by limiting dilution to ensure the generation of
monoclonal populations. Cells were allowed to expand and then char-
acterized for a decrease in mRNA expression in the case of DNAL1, or
a decrease in protein expression in the case of MAP4.
DNAL1 cDNA quantiﬁcation
HeLa cellswere transfectedwith siRNAs for 48 h. Cellswere then har-
vested and total RNA was extracted using the RNeasy Plus Mini Kit
(Qiagen). One microgram of total RNA was reverse transcribed using
the Quanta qScript cDNA SuperMix. 3 μg of the total reaction was then
analyzed by quantitative real-time PCRusing iCycler iQ real-time PCRde-
tection system (BioRad)with the following primers speciﬁc to DNAL1: 5′
CCTGGTAAAAGACTG GGCTG 3′ and 5′GGCACTCTCTTGGTTGCTTC 3′, and
previously published β-actin primers (Anderson et al., 2006). The rela-
tive number of β-actin cDNA copies and DNAL1 cDNA copies was deter-
mined with standard curves.
HIV fusion assay
The fusion assay was carried out in HeLa P4.2 cells expressing
CXCR4 and CD4, as previously described (Cavrois et al., 2004). Brieﬂy,
HeLa P4.2 cells were transfected with siRNAs to CD4, DNAL1 or MAP4.
At 48 h after transfection, cells were infected with R7X4-GFPHIV/Vpr-
BLam virus by spinoculation at 16 °C for 2 h and then incubated at
37 °C for 3 h. Cells were then loaded with CCF2-AM for 14 h. Cells
were then trypsinized, ﬁxed, and analyzed by ﬂow cytometry.
DNAL1 and MAP4 knockdown analysis of late reverse transcripts and
2-LTR circles
HeLa P4.2 cells were seeded at a density of 40,000 cells/well in
24-well dishes. Cells were transfected with Dharmacon siRNA pools
to listed proteins or non-targeting, using RNAiMAX lipofectamine
(Invitrogen) to a ﬁnal siRNA concentration of 10 μM. After 24 h, cells
were re-seeded into 24-well plates at a density of 50,000 cells/well.
VSV-G-pseudotyped R7ΔEnvGFPHIV was pretreated with 20 units/ml
DNaseI (Roche) in 10 mMMgCl2 for 60 min at room temperature before
addition to cell monolayers with drug if appropriate. At 48 h of siRNA
transfection, cells were infected with VSV-G pseudotyped R7Δenv-
GFPHIV reporter virus. At 24 h post infection, cells were trypsinized,
and total cellular DNAwas extracted using the DNeasy Blood and Tissue
Kit (Qiagen). One microgram of total cellular DNA was then digested
with DpnI for 4 h at 37 °C. Late reverse transcripts and 2-LTR circles
were assessed using iCycler iQ real-time PCR detection system (BioRad)
with previously published late reverse transcription product primers
(Butler et al., 2001; Dismuke and Aiken, 2006). The number of cells
in each sample was determined by quantitative PCR ampliﬁcation of
β-actin DNA using previously published primers (Anderson et al.,
2006). The amount of each cDNA product or genomic DNA was quanti-
ﬁed using a standard curve generated from 10-fold dilutions of proviral
plasmid.
Protein analysis and western blotting
ForWestern blot analysis, HeLa cells were transfected with siRNAs
to MAP4 for 48 h. Cells were trypsinized, washed with PBS, and resus-
pended in TEN buffer, then lysed with 2× TNEN buffer and loaded in
laemmli buffer. Proteins were resolved by SDS-PAGE, transferred to a
nitrocellulose membrane (Whatman) and probed with anti-MAP4
monoclonal antibody (Sigma), or anti-GAPDH monoclonal antibody
(Chemicon), followed by goat-anti-rabbit 680 nm (Odyssey) or goat
21D.E. Gallo, T.J. Hope / Virology 422 (2012) 13–21anti-mouse 800 nm (Odyssey) secondary antibodies. Western blots
were imaged on an infrared imager.Acknowledgments
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